Alaunos Therapeutics
TCRT
154 hedge funds and large institutions have $270M invested in Alaunos Therapeutics in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 40 increasing their positions, 46 reducing their positions, and 17 closing their positions.
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
28% more call options, than puts
Call options by funds: $2.98M | Put options by funds: $2.32M
5% more funds holding
Funds holding: 146 → 154 (+8)
0.02% more ownership
Funds ownership: 0.32% → 0.34% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 46
20% less capital invested
Capital invested by funds: $336M → $270M (-$66.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$4.06M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$2.25M |
| 3 |
SG Americas Securities
New York
|
+$2.23M |
| 4 |
Two Sigma Investments
New York
|
+$2.21M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.74M |
| 2 |
BlackRock
New York
|
-$1.05M |
| 3 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$690K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$592K |
| 5 |
D.E. Shaw & Co
New York
|
-$463K |
TCRT Hedge Fund Activity: Q3 2020 in Review
154 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2020, worth a combined $270M — down 20% from $336M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TCRT positions and 17 closed out — a net gain of 8 holders — while 40 added to existing stakes and 46 trimmed.
The largest buyer was State Street, adding an estimated $4.06M. The largest seller was Millennium Management, cutting an estimated $1.74M.
- 154 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2020, up from 146 in Q2 2020.
- Funds reported $270M of Alaunos Therapeutics stock for Q3 2020, down 20% quarter-over-quarter.
- 25 funds opened new Alaunos Therapeutics positions in Q3 2020 and 17 closed out, a net change of +8 holders.
- The largest Alaunos Therapeutics buyer in Q3 2020 was State Street, an estimated $4.06M added.
- The largest Alaunos Therapeutics seller in Q3 2020 was Millennium Management, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2020.